Financial reports for Q32 Bio reflect a typical profile for a clinical-stage biopharmaceutical enterprise, characterized by substantial ongoing research and development expenditures and zero commercial product sales revenue. To maintain robust liquidity for advancing its pipeline—including prominent clinical programs for bempikibart—the company has successfully secured substantial capital infusions through underwritten public stock offerings and private placements, maintaining healthy cash reserves relative to its near-term operational burn rate.